PlatformQ Health is prepared for another jam-packed month of digital programs, including both accredited online healthcare provider activities and patient education sessions. These programs are produced in collaboration with some of the leading aligned professional organizations, centers of excellence and patient advocacy groups. Despite recent travel and in-person meeting restrictions due to COVID-19, the PlatformQ Health production team has kept scheduled partner programs on timeline by leveraging their proprietary software, virtual event and videobridge technology, allowing the program speakers and attendees to engage in discussion from the safety of their own homes with the ability to measure improvements in patient and provider health outcomes.
This month, PlatformQ Health is presenting education that has been developed and disseminated with the following key partners:
- National Organization for Rare Disorders (NORD)
- Cure SMA
- The Consortium Of Multiple Sclerosis Center (CMSC)
- BrightFocus Foundation (BFF)
- Society for Immunotherapy of Cancer (SITC)
- Melanoma Research Foundation (MFA)
- Large Urology Group Practice Association (LUGPA)
Upcoming July Programs
July 13th at 12PM ET: Post-Gene Replacement Treatment SMA Phenotypes and Multidisciplinary Care
In this upcoming CME session produced in partnership with the National Organization for Rare Disorders (NORD) and Cure SMA, top experts Julie A. Parsons, MD, Richard Shell, MD, Linda P. Lowes, PT, PhD, Mary Schroth, MD, will discuss the evolution of SMA phenotypes that may be associated with gene replacement therapy. Additionally, this educational program will also identify best practices for multidisciplinary post-treatment management of patients with SMA who have received gene replacement therapy. Get the latest medical science and earn 1 AMA PRA Category 1 Credit™.
July 15th at 1PM ET: Precision Medicine with Polypharmacy in Multiple Sclerosis: What does it mean in practice?
This upcoming CME program produced in collaboration with The Consortium Of Multiple Sclerosis Center (CMSC) airs on NeuroSeriesLive and will feature speakers, Robert K. Shin, MD, FANA, FAAN, Marijean Buhse, PhD, RN, NP-C, MSCN, Jacquelyn L. Bainbridge, PharmD, FCCP. The expert panel will summarize approaches to providing personalized medicine for MS diagnosis and management while minimizing drug interactions with medications for common comorbidities. Additionally, they will appraise current data on biomarkers for differentiating MS from other disorders and MS phenotypes and evaluate algorithms and predictive models for MS management. Learners may earn up to 1 AMA PRA Category 1 CreditTM through this certified activity.
July 20th at 2PM ET: Alzheimer’s Disease: What Should We Watch for? & What Can We Do Today and Tomorrow?
This program is a multi-session patient and caregiver education program on NeuroCareLive that explores Alzheimers Disease and is produced in partnership with BrightFocus Foundation. In the first session, Alzheimer’s Disease: What Should We Watch For? the expert panel will describe the signs and symptoms of Alzheimer’s Disease (AD) and explain the implications of an early and accurate diagnosis. Following session one, session two, Alzheimer’s Disease: What Can We Do Today and Tomorrow? will begin at 2:30pm EDT on NeuroCareLive. The expert panel will continue their discussion by evaluating current and emerging treatment options for AD. Additionally, they will also identify resources for support and further information available online for patients, families and caregivers who are coping with AD.
July 20th at 12PM ET: Early Diagnosis and Management of Alzheimer’s Disease: Is Now the Time for Disease-Modifying Agents?
In this CME Session airing on NeuroSeriesLive and PsychiatryCareLive, expert faculty Marwan N. Sabbagh, MD, FAAN, CCRI and Stephen P. Salloway, MD, MS will be providing expert recommendations for the optimal early detection of AD, specifically discussing how proactive evaluation of all cognitive domains and biomarkers, as needed, can help achieve an accurate and early diagnosis of mild cognitive impairment and early AD. They will also examine the therapeutic implications of current data on disease-modifying immunotherapies and other agents in late-stage clinical development aimed at slowing disability progression. Learners may earn up to 1 AMA PRA Category 1 CreditTM through this certified activity.
July 24th at 12PM ET: Optimizing Management of Adverse Events Associated with Immunotherapy
This interactive online CME session will be available to watch on OMedLive and is produced in partnership with the Society for Immunotherapy of Cancer (SITC). Expert panelists, Michael Overman, MD and Michelle Rohlfs, MSN, APRN, FNP-BC, AOCNP will lead a discussion about anticipating unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors along with implementing expert-recommended best practices for managing adverse effects that can occur with immunotherapy. Get the latest medical science and earn 1 AMA PRA Category 1 Credit™.
July 24th at 1PM ET: Life After Immunotherapy: Coordinating Care and Survivorship Plans
Immediately following the second session on OMedLive, Michael Overman, MD will lead another CME activity with a multidisciplinary panel that discusses how effective survivorship care requires coordination among a team of specialists, as well as counseling and education that enables patients to effectively manage their post-treatment health and well-being. As the long-term effects of checkpoint inhibitors are incorporated into survivorship planning, the panel will discuss evidence-based strategies to provide a framework to address the unique needs of patients treated with immunotherapy. Participate in this program to get up-to-date medical science and earn1 AMA PRA Category 1 Credit™.
July 28th at 12PM ET: How Will New Data Change nmCRPC
This program produced in collaboration with LUGPA, will analyze new data that has emerged from 3 key trials in non-metastatic castration-resistant prostate cancer (nmCRPC), expert panel presenting a summary of the overall survival data and discussing the impact on treatment decisions. Hear from Dr. Neal Shore, Dr. Daniel George, and Dr. Charles Ryan as they compare urology vs oncology approaches, incorporating current literature, and reviewing ongoing clinical trials in nmCRPC.
Want more information about one of these activities or our production process? Email us at email@example.com